Improving Radiological Outcomes in Arterial Disease - A Pilot Evaluation of the Pedra Tissue Perfusion Monitoring System (IROAD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Addenbrooke's Hospital, Department of Vascular Surgery
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The 3 distinct subjects groups are divided as such:
- Critical Limb Ischaemia (CLI) Group with tibial arterial disease: Up to 20, but at least 8 subjects with a Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels. The treatment of SFA stenoses of less than 70%, as confirmed by duplex or CT, is acceptable in parallel in this group.
- Peripheral Artery Disease (PAD) Group with SFA disease: Up to 20, but at least 8 subjects with a clinical diagnosis of claudication and duplex or CT-confirmed SFA stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.
- PAD-free Group (Healthy Volunteer Group): Up to 20 subjects with no clinical diagnosis of peripheral vascular disease.
Description
General Inclusion Criteria:
- The patient is a male or non-pregnant female ≥ 40 to 90 years of age
- The patient is willing to comply with protocol-specified follow-up evaluations
- The patient has been informed of the nature of the study, agrees to its provisions and has willingly provided written informed consent, approved by the appropriate Ethics Committee (EC)
Cohort Specific Inclusion Criteria:
Critical Limb Ischaemia Group Inclusion Criteria:
- The subject is referred for a percutaneous peripheral revascularisation procedure on one of their lower limbs within 2 weeks of Baseline assessments.
- Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels.
Peripheral Arterial Disease Group Inclusion Criteria:
- The subject is referred for a percutaneous peripheral revascularisation procedure on one of their lower limbs within 2 weeks of Baseline assessments.
- This subject must have a clinical diagnosis of claudication and duplex or CT-confirmed SFA or popliteal artery stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.
PAD-Free Group Inclusion Criteria:
- The subject is recruited voluntarily
- Absence of peripheral vascular disease determined by questionnaire and clinical review (triphasic signals on hand-held Doppler)
Exclusion Criteria:
- Infusion of vasoactive medications within the past 24 hours
- The presence of a known chronic history of anaemia (i.e. Hb <8g/dL)
- Congestive heart failure defined by NYHA Classification 3 or 4
- The absence of intact skin at suitable measurement sites on the foot.
- The presence of invasive soft tissue infection in the toes spreading into the forefoot.
- The presence of physical impediment to the method of measurements being completed (i.e. absent first two toes, extensive ulceration, excessive oedema, pressure dressings or heavy bandaging, etc.)
- The presence of a non-salvageable foot or a Rutherford 6 wound.
- The presence of other conditions, which in the opinion of the Investigator, may compromise the subject safety or comfort.
- The presence of other conditions, which in the opinion of the Investigator, may compromise the accuracy of the data obtained.
- The patient is a vulnerable or protected adult, or is unable to provide consent.
- The patient is unable to comply with the measurement protocol.
- Pregnant subjects
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Critical Limb Ischaemia (CLI) Group with tibial arterial dis
Up to 20, but at least 8 subjects with a Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels.
The treatment of SFA stenoses of less than 70%, as confirmed by duplex or CT, is acceptable in parallel in this group.
|
This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom.
Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group.
Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol.
All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
|
|
Peripheral Artery Disease (PAD) Group with SFA disease
Up to 20, but at least 8 subjects with a clinical diagnosis of claudication and duplex or CT-confirmed SFA stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.
|
This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom.
Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group.
Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol.
All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
|
|
PAD-free group (Healthy Volunteer Group)
Up to 20 subjects with no clinical diagnosis of peripheral vascular disease.
|
This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom.
Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group.
Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol.
All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Baseline safety endpoint: The absence of immediately observable skin reaction (rash; local oedema, blistering of the skin) in ≥ 90% of subjects after removal of the Pedra sensors.
Time Frame: Baseline visit: 30-60 minutes after pad removal
|
This observation assessment is completed by the physician post removal of the adhesive pads.
It is either a "yes" or a "no" in observing if there is a skin reaction to the adhesive pads when they are removed from the skin and also documentation of what type of reaction (rash; local oedema, blistering of the skin).
|
Baseline visit: 30-60 minutes after pad removal
|
|
During procedure safety endpoint: The absence of immediately observable skin reaction (rash; local oedema, blistering of the skin) in ≥ 90% of subjects after removal of the Pedra sensors.
Time Frame: During procedure visit: 30-60 minutes after pad removal
|
This observation assessment is completed by the physician post removal of the adhesive pads.
It is either a "yes" or a "no" in observing if there is a skin reaction to the adhesive pads when they are removed from the skin and also documentation of what type of reaction (rash; local oedema, blistering of the skin).
|
During procedure visit: 30-60 minutes after pad removal
|
|
36-hrs post-procedure/ discharge visit safety endpoint: The absence of immediately observable skin reaction (rash; local oedema, blistering of the skin) in ≥ 90% of subjects after removal of the Pedra sensors.
Time Frame: 36-hrs post-procedure/ discharge visit: 30-60 minutes after pad removal
|
This observation assessment is completed by the physician post removal of the adhesive pads.
It is either a "yes" or a "no" in observing if there is a skin reaction to the adhesive pads when they are removed from the skin and also documentation of what type of reaction (rash; local oedema, blistering of the skin).
|
36-hrs post-procedure/ discharge visit: 30-60 minutes after pad removal
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CIP-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
NCT06319339RecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery Disease
-
NCT04007055TerminatedPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery Disease
-
NCT06832631RecruitingPeripheral Arterial Disease | Peripheral Arterial Occlusive Disease
-
NCT05616169Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery Disease
-
NCT07157475RecruitingPeripheral Arterial Disease(PAD)
-
NCT07142655Completed
-
NCT06389149RecruitingPeripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Peripheral Artery Occlusive Disease
-
NCT04313985TerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular Disease
-
NCT03638115UnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease
-
NCT03935776RecruitingPeripheral Arterial Occlusive Disease
Clinical Trials on Pedra Tissue Perfusion Monitor
-
NCT01296789Terminated
-
NCT03869775UnknownAnesthesia; Adverse Effect
-
NCT01561261CompletedAcute Compartment Syndrome
-
NCT03449524Terminated
-
NCT03412214Completed
-
NCT03060798Completed
-
NCT01169506Completed
-
NCT00493376Terminated
-
NCT06847737Not yet recruiting
-
NCT02233023Completed